Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Protagonist Therapeutics (PTGX) EBITDA (2017 - 2025)

Protagonist Therapeutics' EBITDA history spans 9 years, with the latest figure at -$50.4 million for Q4 2025.

  • For Q4 2025, EBITDA fell 139.72% year-over-year to -$50.4 million; the TTM value through Dec 2025 reached -$158.1 million, down 162.54%, while the annual FY2025 figure was -$158.1 million, 162.54% down from the prior year.
  • EBITDA for Q4 2025 was -$50.4 million at Protagonist Therapeutics, down from -$46.4 million in the prior quarter.
  • Across five years, EBITDA topped out at $206.3 million in Q1 2024 and bottomed at -$50.4 million in Q4 2025.
  • The 5-year median for EBITDA is -$36.3 million (2022), against an average of -$9.0 million.
  • The largest annual shift saw EBITDA crashed 336.52% in 2021 before it skyrocketed 672.75% in 2024.
  • A 5-year view of EBITDA shows it stood at -$37.0 million in 2021, then grew by 1.35% to -$36.5 million in 2022, then soared by 374.18% to $100.1 million in 2023, then increased by 26.63% to $126.8 million in 2024, then tumbled by 139.72% to -$50.4 million in 2025.
  • Per Business Quant, the three most recent readings for PTGX's EBITDA are -$50.4 million (Q4 2025), -$46.4 million (Q3 2025), and -$42.0 million (Q2 2025).